CO5580838A2 - Productos biologicos - Google Patents
Productos biologicosInfo
- Publication number
- CO5580838A2 CO5580838A2 CO04041969A CO04041969A CO5580838A2 CO 5580838 A2 CO5580838 A2 CO 5580838A2 CO 04041969 A CO04041969 A CO 04041969A CO 04041969 A CO04041969 A CO 04041969A CO 5580838 A2 CO5580838 A2 CO 5580838A2
- Authority
- CO
- Colombia
- Prior art keywords
- sec
- seq
- antibody molecule
- rdc
- variable domain
- Prior art date
Links
- 235000018734 Sambucus australis Nutrition 0.000 abstract 1
- 244000180577 Sambucus australis Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Jellies, Jams, And Syrups (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
1.- Una molécula de anticuerpo que tiene especificidad para RDQ humano, que comprende una cadena pesada, donde el dominio variable comprende una RDC que tiene la secuencia dada como H1 en la Figura 1 (SEC. ID. No. 1) para RDCH1, como H2 en la Figura 1 (SEC. ID No.2) o como H3 en Figura 1 (SEC. ID. No 3) para RDCH3.2.- Una molécula de anticuerpo que tiene especificidad para RDQ humano, que comprende una cadena liviana, donde el dominio variable comprende una RDC que tiene la secuencia dada como L1 en la Figura 1 (SEC. ID. No. 4) para RDCL1, como L2 en la Figura 1 (SEC. ID No.5) para RDCL2, o como L3 en Figura 1 (SEC. ID. No 6) para RDCL3.3.- La molécula de anticuerpo de la reivindicación 1 o la reivindicación 2, que comprende una cadena pesada donde el dominio variable comprende un ROQ que tiene la secuencia dada en la SEC. ID. NO. 1 para RDCH1, SEC. ID. No. 2 para RDCH2 o SEC. ID. No. 3 para RDCH3, y una cadena liviana donde el dominio variable comprende una RDC que tiene la secuencia dada en la SEC. ID. No. 4 para RDCL1, SEC: ID. No. 5 para RDCL2, o SEC: ID. No. 6 para RDCL3.4.- La molécula de anticuerpo de la reivindicación 3, que comprende la SEC. ID. NO. 1 para RDCH1, SECo ID. No. 2 para RDCH2 o SEC. ID. No. 3 para RDCH3, SEC. ID. No. 4 para RDCL1, SEC: ID: No. 5 para RDCL2, o SEC: ID. No. 6 para RDCL3.5.- La molécula de anticuerpo de cualquiera de las reivindicaciones 1 a 4, que es una molécula de anticuerpo injertada a RDC.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0124317.9A GB0124317D0 (en) | 2001-10-10 | 2001-10-10 | Biological products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5580838A2 true CO5580838A2 (es) | 2005-11-30 |
Family
ID=9923562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04041969A CO5580838A2 (es) | 2001-10-10 | 2004-05-06 | Productos biologicos |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7452976B2 (es) |
| EP (1) | EP1438340B1 (es) |
| JP (2) | JP4323312B2 (es) |
| KR (2) | KR101018908B1 (es) |
| CN (1) | CN1568331A (es) |
| AT (1) | ATE482234T1 (es) |
| AU (1) | AU2002334135B8 (es) |
| BR (1) | BR0212756A (es) |
| CA (1) | CA2458464A1 (es) |
| CO (1) | CO5580838A2 (es) |
| DE (1) | DE60237778D1 (es) |
| DK (1) | DK1438340T3 (es) |
| EA (1) | EA010970B1 (es) |
| ES (1) | ES2351208T3 (es) |
| GB (1) | GB0124317D0 (es) |
| HU (1) | HUP0401618A3 (es) |
| IL (1) | IL160849A0 (es) |
| IS (1) | IS7173A (es) |
| MX (1) | MXPA04003274A (es) |
| NO (1) | NO20040987L (es) |
| NZ (1) | NZ532758A (es) |
| PL (1) | PL208848B1 (es) |
| WO (1) | WO2003031475A2 (es) |
| ZA (1) | ZA200401910B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0129105D0 (en) * | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| KR101215218B1 (ko) | 2003-07-22 | 2012-12-26 | 바이엘 파마 악티엔게젤샤프트 | Ｒｇ１ 항체 및 그의 용도 |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| AU2005287406B2 (en) | 2004-07-26 | 2011-08-18 | Biogen Ma Inc. | Anti-CD154 antibodies |
| US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| EP2374887A3 (en) * | 2005-03-25 | 2012-07-18 | National Research Council Of Canada | Method for isolation of soluble polypeptides |
| GB0520169D0 (en) * | 2005-10-04 | 2005-11-09 | Celltech R&D Ltd | Biological products |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| CL2007002070A1 (es) | 2006-07-14 | 2008-02-08 | Ac Immune S A Genentech Inc | Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| MX2009010120A (es) | 2007-03-22 | 2009-10-19 | Ucb Pharma Sa | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| AU2008311367B2 (en) | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| AU2010216152B2 (en) | 2009-02-17 | 2015-05-14 | Ucb Biopharma Sprl | Antibody molecules having specificity for human OX40 |
| CN101531718B (zh) * | 2009-04-22 | 2011-11-02 | 中国人民解放军南京军区军事医学研究所 | 抗VEGFR-2抗体嵌合Fab抗体片段及其制备方法、应用 |
| HUE040306T2 (hu) | 2009-09-24 | 2019-03-28 | Ucb Biopharma Sprl | Baktériumtörzs rekombináns fehérje expresszálására, amely tartalmaz proteázhiányos, de chaperonaktivitását megtartott DEGP-t és génkiütött TSP és PTR gént |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
| WO2012016173A2 (en) | 2010-07-30 | 2012-02-02 | Ac Immune S.A. | Safe and functional humanized antibodies |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| HUE035674T2 (en) | 2011-07-13 | 2018-05-28 | Ucb Biopharma Sprl | Bacterial host strains expressing recombinant DSBC |
| BR112014010774A2 (pt) | 2011-11-02 | 2017-06-13 | Apexigen Inc | anticorpos anti-kdr e métodos de uso |
| UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| WO2013125891A1 (ko) | 2012-02-24 | 2013-08-29 | (주)알테오젠 | 시스테인 잔기를 포함하는 모티프가 결합된 변형항체, 상기 변형항체를 포함하는 변형항체-약물 접합체 및 그 제조방법 |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
| CN104870476B (zh) | 2012-11-21 | 2018-04-13 | 药物抗体公司 | 靶向vegfr‑2和dll4的双靶向抗体及包含它的药物组合物 |
| TW201902927A (zh) | 2017-04-21 | 2019-01-16 | 美商梅利特公司 | 糖尿病相關應用之方法及抗體 |
| US20220031841A1 (en) * | 2018-09-19 | 2022-02-03 | Totient, Inc. | Cancer associated antibody compositions and methods of use |
| WO2020132654A1 (en) * | 2018-12-20 | 2020-06-25 | Albert Einstein College Of Medicine | Antagonist antibodies against human immune checkpoint ceacam1 (cd66a) and formulations, kits, and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB8903022D0 (en) | 1989-02-10 | 1989-03-30 | Celltech Ltd | Chemical compounds |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| CN1173991C (zh) | 1992-11-13 | 2004-11-03 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
| DE19638745C2 (de) * | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US6133426A (en) * | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| DE69838334T2 (de) | 1997-06-18 | 2008-06-12 | Merck & Co., Inc. (A New Jersey Corp.) | Kdr, ein menschlicher tyrosin kinase rezeptor |
| WO1999059636A1 (fr) * | 1998-05-20 | 1999-11-25 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf) |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| JP2002536968A (ja) * | 1999-01-29 | 2002-11-05 | イムクローン システムズ インコーポレイティド | Ｋｄｒに特異的な抗体およびその使用 |
-
2001
- 2001-10-10 GB GBGB0124317.9A patent/GB0124317D0/en not_active Ceased
-
2002
- 2002-10-10 CN CNA028202104A patent/CN1568331A/zh active Pending
- 2002-10-10 EP EP02800666A patent/EP1438340B1/en not_active Expired - Lifetime
- 2002-10-10 HU HU0401618A patent/HUP0401618A3/hu unknown
- 2002-10-10 AU AU2002334135A patent/AU2002334135B8/en not_active Ceased
- 2002-10-10 BR BR0212756-3A patent/BR0212756A/pt not_active IP Right Cessation
- 2002-10-10 KR KR1020047005051A patent/KR101018908B1/ko not_active IP Right Cessation
- 2002-10-10 ES ES02800666T patent/ES2351208T3/es not_active Expired - Lifetime
- 2002-10-10 PL PL370344A patent/PL208848B1/pl not_active IP Right Cessation
- 2002-10-10 MX MXPA04003274A patent/MXPA04003274A/es active IP Right Grant
- 2002-10-10 AT AT02800666T patent/ATE482234T1/de not_active IP Right Cessation
- 2002-10-10 NZ NZ532758A patent/NZ532758A/en not_active IP Right Cessation
- 2002-10-10 IL IL16084902A patent/IL160849A0/xx not_active IP Right Cessation
- 2002-10-10 CA CA002458464A patent/CA2458464A1/en not_active Abandoned
- 2002-10-10 US US10/492,228 patent/US7452976B2/en not_active Expired - Fee Related
- 2002-10-10 EA EA200400519A patent/EA010970B1/ru not_active IP Right Cessation
- 2002-10-10 KR KR1020077023689A patent/KR20070116110A/ko not_active Application Discontinuation
- 2002-10-10 JP JP2003534457A patent/JP4323312B2/ja not_active Expired - Fee Related
- 2002-10-10 WO PCT/GB2002/004619 patent/WO2003031475A2/en active Application Filing
- 2002-10-10 DK DK02800666.6T patent/DK1438340T3/da active
- 2002-10-10 DE DE60237778T patent/DE60237778D1/de not_active Expired - Lifetime
-
2004
- 2004-03-05 IS IS7173A patent/IS7173A/is unknown
- 2004-03-08 NO NO20040987A patent/NO20040987L/no not_active Application Discontinuation
- 2004-03-09 ZA ZA200401910A patent/ZA200401910B/en unknown
- 2004-05-06 CO CO04041969A patent/CO5580838A2/es not_active Application Discontinuation
-
2007
- 2007-10-30 US US11/928,880 patent/US7842787B2/en not_active Expired - Fee Related
-
2008
- 2008-11-18 JP JP2008294819A patent/JP2009108086A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5580838A2 (es) | Productos biologicos | |
| ATE411082T1 (de) | Neue verwendung von kurzkettigen carbonsäuren | |
| IS2834B (is) | Aðferðir til þess að meðhöndla gigtarsjúkdóma með því að nota leysanlega CTLA4-sameind | |
| CY1108728T1 (el) | Μονοαλυσωτο μοριο πολλαπλης αντιγονοδεσμευσης, η παραγωγη και η χρηση αυτου | |
| ATE267830T1 (de) | Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen | |
| UY26249A1 (es) | Moléculas pequenas útiles en el tratamiento de las enfermedades inflamatorias ley 17164 art. 127 | |
| CO4480111A1 (es) | Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes | |
| RS54046B1 (en) | ANTI-MIOSTATIN ANTITELA | |
| DE60033530D1 (de) | Humane antikörper gegen ctla-4 und deren verwendungen | |
| ECSP105739A (es) | Anticuerpos de neutralización contra gdf-8 | |
| BR0314814A (pt) | Variantes otimizadas de fc e métodos para sua geração | |
| BR0011838A (pt) | Elementos misturadores estáticos empilhados | |
| SI1644484T1 (sl) | Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah | |
| BR0113798A (pt) | Derivados de resorcinol | |
| WO2001098317A3 (en) | Alpha-glycosylceramides for treating bacterial and fungal infections | |
| EA200601191A1 (ru) | Продукты для ухода за ранами, содержащие кератин | |
| ATE395082T1 (de) | Antikörper gegen krebsantigen tmeff2 und seine anwendungen | |
| AR063026A1 (es) | Anticuerpos dirigidos contra ccr5 y la utilizacion de los mismos | |
| DE60332488D1 (de) | MIT PrP sp sc/sp WECHSELWIRKENDE MOLEKÜLE UND DEREN VERWENDUNG | |
| HK1154904A1 (zh) | 天然 抗體及其抑制劑 | |
| NL1024616A1 (nl) | Depotpreparaten in de vorm van een suspensie. | |
| DE60324779D1 (de) | Antikörperbibliotheken | |
| AR032548A1 (es) | Metodo y composicion para desinfectar una superficie contaminada con una proteina prion | |
| ES2042461T1 (es) | Producto y procedimiento para el te\ido oxidativo del cabello. | |
| ATE527280T1 (de) | Fluoreszentprotein und chromoprotein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted | ||
| FD | Application lapsed |